Ionis Pharmaceuticals
bepirovirsen
chronic hepatitis B
Resolved
37days ago
Phase 3 readout · ~ May 31, 2026 estimated
What's at stake
Phase 3 trial results for bepirovirsen in chronic hepatitis B are due ~ May 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“GSK to present the positive Phase 3 data at the European Association for the Study of the Liver (EASL) Congress 2026 next month”